Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM
Authors |
Magnus Gisslén Gunnar Norkrans Bo Svennerholm Lars Hagberg |
---|---|
Published in | J Infect Dis |
Volume | 175 |
Issue | 2 |
Pages | 434-7 |
Publication year | 1997 |
Published at |
Institute of Internal Medicine, Dept of Infectious Diseases Institute of Laboratory Medicine, Dept of Clinical Virology |
Pages | 434-7 |
Language | en |
Links |
www.ncbi.nlm.nih.gov/entrez/query.f... |
Keywords | Adult, Aged, Anti-HIV Agents/*therapeutic use, Biopterin/analogs & derivatives/analysis, Didanosine/*therapeutic use, HIV Infections/blood/cerebrospinal fluid/*drug therapy, HIV-1/*growth & development, Humans, Middle Aged, Neopterin, RNA, Viral/*analysis, *Viral Load, Zidovudine/*therapeutic use, beta 2-Microglobulin/analysis |
Subject categories | Microbiology in the medical area |
Human immunodeficiency virus type 1 (HIV-1) RNA, neopterin, and beta2-microglobulin levels were analyzed in cerebrospinal fluid (CSF) and serum before and 3-13 months after initiation of antiretroviral monotherapy in 16 HIV-1-infected persons. Twenty-one treatment periods, 13 after initiation of zidovudine and 8 after initiation of didanosine, were studied. During zidovudine treatment, CSF HIV RNA levels decreased by a mean of 1.05 log10 (-91%, P < .01), and CSF neopterin and beta2-microglobulin levels by 57% and 33%, respectively (P < .01). No reduction was seen during didanosine treatment in CSF HIV RNA (+0.13 log10, not significant), CSF neopterin, or beta2-microglobulin levels. Changes in CSF HIV RNA levels correlated with changes in CSF neopterin and beta2-microglobulin (r(s) = .81 and .83, respectively, P < .001). The decrease in HIV RNA was significantly larger in CSF than in serum following zidovudine treatment (P < .01). These data demonstrate that zidovudine is a potent reducer of central nervous system virus load, which may be important for long-term neuroprotection.